$TGTXTG THERAPEUTICS, INC.

Active trials

• phase2Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophreniarecruitingn=60
• phase2A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)recruitingn=350
• —A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)recruitingn=2,000
• phase3Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosisrecruitingn=240
• phase3An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosisactive not recruitingn=1,100
• phase3Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximabrecruitingn=800
• phase1A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disordersrecruitingn=32
• —A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milkrecruitingn=16